구독하기
연구 모델
서비스
전임상 효능 평가
Resource
Scn1a-KO Mouse
제품 견적 요청
카탈로그에서 제품을 선택하여 요청을 제출해 주세요. Cyagen 팀이 상세 정보를 제공해 드립니다.
Scn1a-KO Mouse
제품명
Scn1a-KO Mouse
제품 ID
C002015
품종 계통
C57BL/6JCya-Scn1aem1/Cya
Backgroud
C57BL/6JCya
상태
이 마우스 계통을 논문에서 사용할 경우, “Scn1a-KO Mouse (카탈로그 번호 C002015)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
Small Nucleic Acids
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
가격 문의
Small Nucleic Acids
기본 정보
관련 자료
기본 정보
유전자명
유전자 별칭
Nav1.1, B230332M13
NCBI ID
염색체
Chr 2
MGI ID
Datasheet
품종 계통 설명
The SCN1A gene encodes the α subunit of the voltage-gated sodium channel Nav1.1, which is a critical gene for maintaining neuronal excitability regulation and neural signal transmission. Loss-of-function mutations in SCN1A are closely associated with various epilepsy syndromes, with Dravet syndrome (DS) being the most typical example [1]. SCN1A mutations primarily affect GABAergic inhibitory interneurons, leading to impaired inhibitory neural circuits, disruption of the excitation/inhibition (E/I) balance, and increased epilepsy susceptibility [2].
Scn1a-KO mice recapitulate epilepsy phenotypes associated with SCN1A loss-of-function by deleting the mouse Scn1a gene. These models are suitable for anti-epileptic drug screening, validation of SCN1A gene therapy strategies, investigation of epilepsy pathogenesis, and intervention studies of neuropsychiatric comorbidities.
Homozygous Scn1a knockout mice typically exhibit severe neurological abnormalities, including early postnatal lethality, seizures, and pronounced behavioral deficits. Heterozygous knockout mice display spontaneous seizures, premature death, and abnormal neurophysiological activity. Therefore, when studying SCN1A-related disorders, conditional knockout strategies are recommended. These approaches enable tissue- or cell-type-specific regulation of Scn1a deletion, allowing further dissection of how Nav1.1 functional deficits in different neural circuits contribute to epilepsy and associated neurobehavioral abnormalities.
Reference
Martins Custodio H, Clayton LM, Bellampalli R, Pagni S, Silvennoinen K, Caswell R; Genomics England Research Consortium; Brunklaus A, Guerrini R, Koeleman BPC, Lemke JR, Møller RS, Scheffer IE, Weckhuysen S, Zara F, Zuberi S, Kuchenbaecker K, Balestrini S, Mills JD, Sisodiya SM. Widespread genomic influences on phenotype in Dravet syndrome, a 'monogenic' condition. Brain. 2023 Sep 1;146(9):3885-3897.
Mattei C, Mao M, Byars S, Syazwan EM, Oliva M, Karle TJ, Richards K, Scheffer IE, Petrou S, Maljevic S. Disrupted inhibitory interneuron development in SCN1A Dravet syndrome revealed by patient-derived subpallial organoids. Epilepsia. 2026 May 5.
변형 전략
The Scn1a gene is located on chromosome 2 of mice and contains a total of 26 exons. Gene editing technology was used to knock out the region of exon 2 of this gene.

Figure 1. Diagram of the gene editing strategy for the generation of Scn1a-KO mice.
응용 분야
Anti-epileptic drug screening: Used to evaluate the therapeutic efficacy and safety of novel anti-epileptic drugs (e.g., fenfluramine, stiripentol) on thermally induced seizures, spontaneous seizures, and related neurological dysfunctions;
Validation of gene therapy strategies: Used to assess the therapeutic potential of AAV-mediated SCN1A gene replacement therapy, gene editing repair strategies, and transcriptional activation technologies after disease onset;
Epilepsy pathogenesis research: Used to investigate the mechanisms by which SCN1A deficiency leads to reduced excitability of GABAergic interneurons, abnormal inhibitory synaptic transmission, and excitation/inhibition imbalance in neural networks during epilepsy development;
Neuropsychiatric comorbidity research: Used to study the mechanisms and intervention effects of Dravet syndrome (DS)-associated neuropsychiatric comorbidities, including cognitive impairment, abnormal social behavior, anxiety-like behavior, and motor dysfunction;
Disease reversibility research: Used to explore whether restoring Nav1.1 protein expression levels after the appearance of disease phenotypes can reverse epileptic phenotypes, reduce the risk of sudden unexpected death in epilepsy (SUDEP), and improve cognitive and behavioral deficits.
관련 자료
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
